Search Results

Thermo Fisher Scientific Inc. today announced the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP).

Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced it has entered into a definitive agreement to acquire CorEvitas, LLC (“CorEvitas”), a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity (“Audax”), for $912.5 million in cash.

Thermo Fisher Scientific Inc. announced that it has completed the acquisition of CorEvitas, LLC, a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity, for $912.5 million in cash.

Audax Private Equity (“Audax”), a leading alternative investment manager and capital partner for North American middle market companies, announced today it has entered into a definitive agreement to sell CorEvitas, LLC (“CorEvitas”), a leading provider of real-world evidence for regulatory approved medical treatments and therapies, to Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”).

CorEvitas LLC (“CorEvitas”), an industry leader in syndicated registries, announced the acquisition of Pregistry, LLC (“Pregistry”), a global leader in safety studies during pregnancy.

Thermo Fisher Scientific Inc. today announced the launch of CorEvidence, a proprietary cloud-based data lake platform optimizing pharmacovigilance case processing and safety data management processes.

CorEvitas, LLC (“CorEvitas”), a leading provider of syndicated registries, is pleased to share important safety information regarding mRNA COVID-19 vaccines and their use in pregnant people.

CorEvitas, LLC, the leading sponsor of registries in autoimmune and inflammatory diseases announces first patient enrollment in a new biospecimen study for patients enrolled in its rheumatology registries.

Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, today announced new data from the CorEvitas Psoriatic Arthritis (PsA) and Spondyloarthritis Registry that showed a substantial proportion of people living with treatment-resistant active PsA and using TREMFYA® (guselkumab) in real-world settings reported meaningful improvements in pain, physical function and fatigue through six months.